Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Esperion Therapeutics, Inc. - Common Stock
(NQ:
ESPR
)
2.470
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Esperion Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 10, 2026
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
March 03, 2026
From
Corstasis Therapeutics Inc.
Via
Business Wire
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
March 03, 2026
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10
February 24, 2026
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Participate in The 2026 Citizens Life Sciences Conference
February 18, 2026
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040
February 17, 2026
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 11, 2026
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
January 11, 2026
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference
January 05, 2026
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes
December 19, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
December 09, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
November 21, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference
November 19, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
November 18, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) in Oral and Poster Presentations at the AHA Scientific Sessions 2025
November 10, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
November 06, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update
November 06, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer
November 04, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Participate in Jefferies Global Healthcare Conference - London
November 03, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November 11, 2025, at 2:00 p.m. ET.
October 28, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025
October 27, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Report Third Quarter 2025 Financial Results on November 6
October 23, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Nominates ESP-2001 as Preclinical Development Candidate for Treatment of Primary Sclerosing Cholangitis
October 16, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Pricing of Public Offering of Common Stock
October 07, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Proposed Public Offering of Common Stock
October 07, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040
October 03, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
September 19, 2025
Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias
August 29, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Participate in Upcoming September Investor Conferences
August 26, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 07, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
